Medical Cannabis Shows Limited Benefits for Mental Health Disorders
A comprehensive scientific review has cast doubt on the effectiveness of medical cannabis for treating mental health conditions, finding little evidence to support its use for anxiety, depression, and post-traumatic stress disorder.
The study, described as the largest review of medical cannabis to date, examined 54 randomized controlled trials published between 1980 and 2025. Dr. Jack Wilson, the lead researcher from the University of Sydney's Matilda Centre for Research in Mental Health and Substance Use, concluded that medicinal cannabis use for mental health conditions is rarely justified without proper medical supervision.
Limited Evidence for Common Mental Health Conditions
The research team found that cannabis provided no measurable benefit for treating several mental health disorders, including bipolar disorder, anxiety, attention deficit hyperactivity disorder, obsessive-compulsive disorder, anorexia nervosa, and psychotic disorders.
Particularly concerning for depression sufferers, the researchers could not identify any trials testing cannabis as a primary treatment for this widespread condition. This finding is significant given that depression represents one of the most common reasons individuals seek medical cannabis prescriptions.
Dr. Wilson acknowledged that some individuals may experience legitimate benefits from cannabis treatment, but emphasized that the overall evidence does not support routine medical use of these substances for mental health purposes.
Potential Risks and Complications
The study revealed troubling findings regarding substance use disorders. For individuals with cocaine-use disorder, medical cannabis actually increased cravings, potentially worsening their dependency issues.
However, researchers identified one promising application: treating cannabis use disorder itself. Similar to methadone treatment for opioid addiction, cannabis medicines may help individuals reduce their marijuana consumption when combined with psychological therapy.
Some Encouraging Results
Despite the limited mental health applications, the review identified promising findings for other conditions. Cannabis showed potential benefits for reducing symptoms of autism spectrum disorder, improving sleep quality in insomnia cases, and decreasing the severity of tics in Tourette's syndrome.
Dr. Wilson cautioned that the quality of evidence for these conditions remains low, though he described the findings as encouraging and worthy of further investigation.
The research confirmed established benefits of medicinal cannabis in reducing seizures for certain types of epilepsy, easing spasticity in multiple sclerosis, and managing specific types of pain.
Widespread Usage Despite Limited Evidence
Currently, 40 states in the United States, along with the District of Columbia and four territories, have legalized cannabis for medical purposes. Research indicates that 27 percent of people aged 16 to 65 across the United States and Canada have tried medical cannabis, with approximately half using it for mental health management.
This widespread adoption occurs against the backdrop of significant mental health challenges, with more than one in five American adults living with mental illness, representing 59.3 million people in 2022.
Call for Regulatory Caution
The study's findings raise important questions about current approval processes for medicinal cannabis, particularly for conditions like depression, anxiety, and PTSD. Dr. Wilson suggested that routine use of medicinal cannabis could potentially cause more harm than benefit by worsening mental health outcomes and delaying access to more effective treatments.
The research emphasizes the importance of robust medical supervision and counselling support when considering cannabis-based treatments for mental health conditions.